Probenecid, an old β-lactams pharmacokinetic enhancer for a renewed use: A retrospective study.

Anemia, Sickle Cell Anti-Bacterial Agents / therapeutic use Humans Probenecid / pharmacokinetics Retrospective Studies beta-Lactams / therapeutic use
Antibiotic Pharmacokinetics Probenecid Renal hyperfiltration

Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 16 12 2021
revised: 13 04 2022
accepted: 23 05 2022
pubmed: 1 6 2022
medline: 4 8 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Optimized antibiotic plasma predictor efficacy is essential in systemic infections. The uricosuric agent probenecid inhibits tubular excretion of antibiotics and may be used as β-lactam pharmacokinetic enhancer (BLPKE), even though few data are currently available for this purpose. We conducted a monocentric and retrospective observational study including all patients who received probenecid in combination with parenteral β-lactam antibiotics for systemic infections from Jan 1, 2014 to Dec 31, 2019. Demographics, infection characteristics, treatment and ATC (antibiotics trough concentration) were investigated. All in all, 38 patients were included. Eight patients had a history of sickle cell disease. Hyperfiltration (defined as eGFR>130mL/min/1.73m Probenecid could be a BLPKE. Our data suggest this drug should be used more often to optimize β-lactam pharmacokinetics in clinical practice.

Sections du résumé

BACKGROUND BACKGROUND
Optimized antibiotic plasma predictor efficacy is essential in systemic infections. The uricosuric agent probenecid inhibits tubular excretion of antibiotics and may be used as β-lactam pharmacokinetic enhancer (BLPKE), even though few data are currently available for this purpose.
METHODS METHODS
We conducted a monocentric and retrospective observational study including all patients who received probenecid in combination with parenteral β-lactam antibiotics for systemic infections from Jan 1, 2014 to Dec 31, 2019. Demographics, infection characteristics, treatment and ATC (antibiotics trough concentration) were investigated.
RESULTS RESULTS
All in all, 38 patients were included. Eight patients had a history of sickle cell disease. Hyperfiltration (defined as eGFR>130mL/min/1.73m
CONCLUSION CONCLUSIONS
Probenecid could be a BLPKE. Our data suggest this drug should be used more often to optimize β-lactam pharmacokinetics in clinical practice.

Identifiants

DOI: 10.1016/j.idnow.2022.05.006 PMID: 35636701
pubmed: 35636701
pii: S2666-9919(22)00096-3
doi: 10.1016/j.idnow.2022.05.006
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
beta-Lactams 0
Probenecid PO572Z7917

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-279

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

P Huriez (P)

Service de maladies infectieuses et d'immunologie, CHU Henri-Mondor, Créteil, France. Electronic address: pauline.huriez@aphp.fr.

C Ourghanlian (C)

Pharmacie à usage intérieur, unité transversale de traitement des infections, CHU Henri-Mondor, Créteil, France.

K Razazi (K)

Service de réanimation médicale, université Paris-Est, CHU Henri-Mondor, Créteil, France.

W Vindrios (W)

Service de maladies infectieuses et d'immunologie, CHU Henri-Mondor, Créteil, France.

A Hulin (A)

Service de pharmacologie, université Paris-Est Créteil, EA7375, EC2M3 Oncomix-UPEC-Institut Pasteur, CHU Henri-Mondor, Créteil, France.

R Lepeule (R)

Unité transversale de traitement des infections, CHU Henri-Mondor, Créteil, France.

A Habibi (A)

Centre de référence des syndromes drépanocytaires majeurs, UMGGR, CHU Henri-Mondor, U-PEC, IMRB, laboratoire d'excellence Labex GRex, Créteil, France.

S Gallien (S)

Service de maladies infectieuses et d'immunologie, université Paris-Est, CHU Henri-Mondor, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies génétiques congénitales › Hémoglobinopathies › Drépanocytose › Probenecid, an old β-lactams pharmacokinetic...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Probenecid, an old β-lactams pharmacokinetic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Probenecid, an old β-lactams pharmacokinetic...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Probénécide › Probenecid, an old β-lactams pharmacokinetic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Probenecid, an old β-lactams pharmacokinetic...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Probenecid, an old β-lactams pharmacokinetic...